Nuvation Bio (NUVB) Fundamental Analysis: Revenue, Earnings & Valuation

9.42 / 10

Outperform

Fundamental analysis rates NUVB Outperform with a 9.4/10 score. Interest coverage and PB‑ROE are strong, while current‑liabilities ratio and revenue‑MV are weaker. Overall fund score 9.42 reflects solid financial health.

Analysis Checks(6/10)

Revenue-MV

Value-2.17

Score1/3

Weight30.93%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value698.96

Score2/3

Weight0.86%

1M Return0.13%

Inventory turnover ratio

Value1.63

Score1/3

Weight-63.84%

1M Return-11.51%

Current liabilities / Total liabilities (%)

Value28.44

Score1/3

Weight-9.94%

1M Return-1.69%

PB-ROE

Value4.05

Score3/3

Weight78.44%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.42

Score2/3

Weight-2.20%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-7.22%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value698.96

Score2/3

Weight0.35%

1M Return0.05%

Cost of sales ratio (%)

Value14.78

Score1/3

Weight-36.70%

1M Return-7.95%

Asset-MV

Value-0.55

Score3/3

Weight109.34%

1M Return11.61%

Is NUVB undervalued or overvalued?

NUVB scores 9.42/10 on fundamentals and holds a Discounted valuation at present. Backed by its -53.18% ROE, -325.31% net margin, -7.49 P/E ratio, 5.01 P/B ratio, and 71.56% earnings growth, these metrics solidify its Outperform investment rating.